Methylphenidate Plus GWI-Nutrient Formula as a Treatment for Patients With Gulf War Illness

Phase 2 Unknown 30 enrolled K-PAX Pharmaceuticals, Inc. VA Palo Alto Health Care System · collab

NaSingle-groupOpen-labelTreatment

Summary

The Gulf War Synergy Trial will evaluate the safety and efficacy of a currently available medication, methylphenidate (Ritalin®), combined with a GWI Nutrient Formula (K-PAX Synergy) to treat Gulf War Illness (GWI).

Timeline

Start: 2015-01
Primary completion: 2016-05
Completion: 2016-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	K-PAX Synergy	Unknown	4 unknown	—
Subject	Methylphenidate	Small molecule	10 mg	—

Methylphenidate Plus GWI-Nutrient Formula as a Treatment for Patients With Gulf War Illness

Summary

Timeline

Drugs

Indications